Last chance: Invest in KA-EX now
The ongoing crowdfunding campaign of KA-EX on CONDA.ch has entered its final phase. For private investors, this is the moment to invest in a company that has already validated its product, market, and technology before taking its next major growth step.
Over the past few years, KA-EX has evolved from a strong Swiss brand into an internationally scaling functional nutrition company. What makes the business particularly compelling is the combination of science-based products, clear market traction, and a patented technology platform that goes far beyond traditional supplements.
Why KA-EX is especially compelling right now
Today, KA-EX is one of the best-selling supplement brands in Switzerland and has built a strong retail presence. At the same time, the company has successfully entered the US market and already delivered strong early signals there. This combination of local market leadership and international expansion makes the current phase especially relevant.
There is also a clear technology angle: with its patented VICAP technology, KA-EX is able to bring highly effective ingredients that were previously difficult to stabilize into ready-to-drink formats. That means KA-EX is not just a brand, but also a platform for the next generation of functional beverages.
Growth backed by substance
The current campaign is not aimed at investors backing an early-stage idea, but at those who want to participate in an already established company with a clear trajectory. In 2025, KA-EX tripled its revenue year over year and reached an annualized run rate of around USD 7.5 million. The successful US launch, strong distribution channels, and support from strategic investors all underline the strength of the business model.
Well-known names are already behind the company. Investors and brand ambassadors such as Lara Gut-Behrami, together with strategic industry partners, further strengthen the credibility of the brand, the product, and its growth path.
Why this is truly the last chance
The current Pre-Series-B round is intentionally positioned as the final opportunity for private investors before the next major scaling phase. The capital raised is intended to accelerate growth further, especially in the US market and in expanding the company’s technology platform.
For investors, this means entering not at an early and uncertain stage, but at a point where key milestones have already been achieved and the next stage of value creation is being prepared. That is exactly what makes this round especially attractive.
Join the next growth phase now
KA-EX shows how science-based functional nutrition can become an internationally scalable company with a real technological moat. Anyone who wants to explore the opportunity in more detail can find all relevant information about the investment story, milestones, and growth strategy on the campaign page.
